FDA clears Sanofi's Apidra for children

3 November 2008

French drug major Sanofi-Aventis says that the US Food and Drug Administration has approved Apidra (insulin glulisine [rDNA origin] injection) to improve glycemic control in children (four years and older) with diabetes mellitus.

The approval of the drug for pediatric use is based on the FDA's review of a 26-week, Phase III, open-label, active control study of Apidra in comparison with insulin lispro, in 572 children and adolescents (four years and older) with type 1 diabetes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight